BGLC BIONEXUS GENE LAB CORP revenue, earnings and financials
For the quarter ended June 30, 2026, BIONEXUS GENE LAB CORP reported revenue of $76.2K (down 96.6% from a year earlier), net income of −$286K and diluted EPS of −$0.12; over the last four quarters revenue was $3.13M and net income −$2.58M; for the fiscal year ended December 2025 revenue was $7.42M, down 21.9% on the year before.
BGLC annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $7.42M, gross profit $1.09M, operating income −$2.97M, net income −$2.98M (margin -40.2%), EPS n/a
- Fiscal year ended Dec 2024: revenue $9.51M, gross profit $1.29M, operating income −$1.57M, net income −$1.60M (margin -16.8%), EPS −$0.09
- Fiscal year ended Dec 2023: revenue $9.77M, gross profit $1.33M, operating income −$2.59M, net income −$2.63M (margin -26.9%), EPS −$0.17
- Fiscal year ended Dec 2022: revenue $10.9M, gross profit $1.26M, operating income −$291K, net income −$356K (margin -3.3%), EPS n/a
- Fiscal year ended Dec 2021: revenue $13.4M, gross profit $2.27M, operating income $1.06M, net income $752K (margin 5.6%), EPS n/a
BGLC quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $76.2K (down 96.6% year over year), net income −$286K, EPS −$0.12
- Quarter ended Mar 31, 2026: revenue $22.8K (down 98.9% year over year), net income −$544K, EPS −$0.23
- Quarter ended Dec 31, 2025 (from the annual report): revenue $484K (down 80.8% year over year), net income −$1.04M, EPS n/a
- Quarter ended Sep 30, 2025: revenue $2.54M (down 3.3% year over year), net income −$709K, EPS −$0.40
- Quarter ended Jun 30, 2025: revenue $2.26M (up 14.5% year over year), net income −$616K, EPS −$0.34
- Quarter ended Mar 31, 2025: revenue $2.14M (down 10.3% year over year), net income −$623K, EPS −$0.35
- Quarter ended Dec 31, 2024 (from the annual report): revenue $2.52M (up 11.0% year over year), net income −$348K, EPS $0.55
- Quarter ended Sep 30, 2024: revenue $2.63M (up 3.0% year over year), net income −$1.35M, EPS −$0.75
- Quarter ended Jun 30, 2024: revenue $1.97M (down 23.1% year over year), net income $199K, EPS $0.11
- Quarter ended Mar 31, 2024: revenue $2.38M (up 0.2% year over year), net income −$104K, EPS −$0.01
- Quarter ended Dec 31, 2023 (from the annual report): revenue $2.27M (down 20.0% year over year), net income $308K, EPS n/a
- Quarter ended Sep 30, 2023: revenue $2.55M (down 0.8% year over year), net income −$2.61M, EPS n/a
- Quarter ended Jun 30, 2023: revenue $2.57M (up 3.3% year over year), net income −$259K, EPS n/a
- Quarter ended Mar 31, 2023: revenue $2.38M (down 21.5% year over year), net income −$69.1K, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue $2.84M (down 12.5% year over year), net income −$157K, EPS n/a
- Quarter ended Sep 30, 2022: revenue $2.58M (down 28.0% year over year), net income −$77.4K, EPS n/a
- Quarter ended Jun 30, 2022: revenue $2.49M (down 19.6% year over year), net income −$139K, EPS n/a
- Quarter ended Mar 31, 2022: revenue $3.03M (down 12.2% year over year), net income $17.1K, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue $3.25M, net income $89.2K, EPS n/a
- Quarter ended Sep 30, 2021: revenue $3.58M, net income $295K, EPS $0.00
BGLC cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$1.84M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$2.09M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$1.82M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $552K, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $9.16K, share buybacks n/a
BGLC balance sheet
- Jun 30, 2026: cash $1.23M, total assets $8.73M, total liabilities $948K, shareholders' equity $7.78M
- Mar 31, 2026: cash n/a, total assets $9.04M, total liabilities $947K, shareholders' equity $8.09M
- Dec 31, 2025: cash $2.38M, total assets $9.25M, total liabilities $638K, shareholders' equity $8.61M
- Sep 30, 2025: cash n/a, total assets $7.62M, total liabilities $805K, shareholders' equity $6.82M
- Jun 30, 2025: cash n/a, total assets $9.42M, total liabilities $1.90M, shareholders' equity $7.52M
- Mar 31, 2025: cash n/a, total assets $9.48M, total liabilities $1.71M, shareholders' equity $7.77M
- Dec 31, 2024: cash $2.89M, total assets $10.4M, total liabilities $2.11M, shareholders' equity $8.32M
- Sep 30, 2024: cash n/a, total assets $11.0M, total liabilities $1.61M, shareholders' equity $9.39M
What is BGLC's revenue?
BIONEXUS GENE LAB CORP reported $3.13M of revenue over its last four quarters, through June 30, 2026.
Is BGLC profitable?
No. BIONEXUS GENE LAB CORP lost $2.58M over the last four quarters.